Log In
Print
BCIQ
Print
Print this Print this
 

TTI-1612

  Manage Alerts
Collapse Summary General Information
Company Stem Cell Therapeutics Corp.
DescriptionRecombinant heparin-binding EGF-like growth factor (HBEGF; DTR) with cytoprotective and anti-inflammatory effects
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationCystitis
Indication DetailsTreat interstitial cystitis/bladder pain syndrome (IC/BPS)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today